ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 283,200 shares, an increase of 47.6% from the October 31st total of 191,900 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average daily volume of 122,700 shares, the short-interest ratio is currently 2.3 days.

Institutional Trading of ABIVAX Société Anonyme

A number of hedge funds have recently bought and sold shares of ABVX. Point72 Asset Management L.P. lifted its holdings in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. Walleye Capital LLC increased its stake in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the period. BNP Paribas Financial Markets grew its stake in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. abrdn plc raised its stake in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after acquiring an additional 198,225 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after purchasing an additional 131,414 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Stock Down 0.4 %

Shares of NASDAQ ABVX opened at $8.53 on Friday. ABIVAX Société Anonyme has a 1-year low of $8.23 and a 1-year high of $17.02. The business’s fifty day moving average price is $10.05 and its two-hundred day moving average price is $11.77.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.